Diagnosis and Risk Factors for Invasive Mold Infections
Main page content
This competitive program seeks to encourage organizations to submit grant applications for independent educational activities for health care professionals involved in the diagnosis and management of patients with invasive fungal infections (IFI). Individual projects requesting up to $75,000 USD will be considered.
Applicant Eligibility Criteria
• Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
• The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
• If the project involves multiple departments within an institution and/or between different institutions /organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
• The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead’s grant coordinator).
• The project/program lead must be an employee or contractor of the requesting organization. • Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.